D. Porter

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Matthew A. Wiles, Manisha, Christopher M. Horvat, 2021, Intensive Care Medicine.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Matthew A. Wiles, Nerissa C. Brown, Christopher M. Horvat, 2022, JAMA.

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

M. Highley, A. Boddy, M. Cole, 2002, British journal of clinical pharmacology.

Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters

D. Newell, S. Kaul, H. Thomas, 1996, Journal of Pharmacokinetics and Biopharmaceutics.

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.

A. Boddy, D. Newell, A. Calvert, 1996, Seminars in oncology.

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports

K. Brickell, D. Porter, P. Thompson, 2003, British Journal of Cancer.